Integrative transcriptomic analysis reveals diagnostic biomarkers for comorbidity of coronary artery disease and obstructive sleep apnea.

IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Frontiers in Cardiovascular Medicine Pub Date : 2025-09-17 eCollection Date: 2025-01-01 DOI:10.3389/fcvm.2025.1658016
Qingquan Liu, Xiaoyu Chen, Shuhan Chen, Hongzhi Gao, Meiting He, Yingting Shi, Mingzhu Zhao, Liying Yu, Huili Lin
{"title":"Integrative transcriptomic analysis reveals diagnostic biomarkers for comorbidity of coronary artery disease and obstructive sleep apnea.","authors":"Qingquan Liu, Xiaoyu Chen, Shuhan Chen, Hongzhi Gao, Meiting He, Yingting Shi, Mingzhu Zhao, Liying Yu, Huili Lin","doi":"10.3389/fcvm.2025.1658016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The co-occurrence of coronary artery disease (CAD) and obstructive sleep apnea (OSA), termed CADOSA, leads to worse clinical outcomes than either condition alone, yet its molecular mechanisms remain unclear, necessitating biomarker discovery for improved diagnosis and personalized management.</p><p><strong>Methods: </strong>This study enrolled 96 age-matched participants (24 healthy controls, 25 CAD, 23 OSA, and 24 CADOSA) for clinical assessment and PBMC transcriptomic profiling. Integrated bioinformatics analyses included differential gene expression (edgeR/DESeq2), pathway enrichment, protein-protein interaction networks and topological analysis, machine learning-based biomarker selection, and immune cell infiltration evaluation.</p><p><strong>Results: </strong>CADOSA patients had more severe cardiac dysfunction (enlarged left ventricle), respiratory impairment (higher apnea-hypopnea index), and metabolic disturbances (elevated triglycerides/creatinine) compared to single-disease condition of CAD or OSA. Transcriptomics identified 832 CAD-specific, 166 OSA-specific, and 376 CADOSA-specific DEGs compared to the healthy control. The CADOSA exhibited both shared (impaired efferocytosis, neutrophil extracellular traps, and cytoskeletal abnormalities) and unique enriched pathways (NOD-like receptor/PPAR signaling pathway), predominantly associated with immune or metabolic dysregulation. Enhanced expression of S100A12 and MMP9 genes (AUC = 0.83 and 0.78, respectively) was identified as potential biomarkers for CADOSA, and their upregulation was further confirmed by qRT-PCR. Notably, S100A12 expression was correlated with increased monocyte infiltration, highlighting its role in inflammatory pathogenesis of CADOSA.</p><p><strong>Conclusions: </strong>These findings reveal immune-metabolic dysregulation underlying CADOSA and provide potential diagnostic biomarkers and targeted therapeutic targets (S100A12 and MMP9) for CADOSA patients.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1658016"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484168/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1658016","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The co-occurrence of coronary artery disease (CAD) and obstructive sleep apnea (OSA), termed CADOSA, leads to worse clinical outcomes than either condition alone, yet its molecular mechanisms remain unclear, necessitating biomarker discovery for improved diagnosis and personalized management.

Methods: This study enrolled 96 age-matched participants (24 healthy controls, 25 CAD, 23 OSA, and 24 CADOSA) for clinical assessment and PBMC transcriptomic profiling. Integrated bioinformatics analyses included differential gene expression (edgeR/DESeq2), pathway enrichment, protein-protein interaction networks and topological analysis, machine learning-based biomarker selection, and immune cell infiltration evaluation.

Results: CADOSA patients had more severe cardiac dysfunction (enlarged left ventricle), respiratory impairment (higher apnea-hypopnea index), and metabolic disturbances (elevated triglycerides/creatinine) compared to single-disease condition of CAD or OSA. Transcriptomics identified 832 CAD-specific, 166 OSA-specific, and 376 CADOSA-specific DEGs compared to the healthy control. The CADOSA exhibited both shared (impaired efferocytosis, neutrophil extracellular traps, and cytoskeletal abnormalities) and unique enriched pathways (NOD-like receptor/PPAR signaling pathway), predominantly associated with immune or metabolic dysregulation. Enhanced expression of S100A12 and MMP9 genes (AUC = 0.83 and 0.78, respectively) was identified as potential biomarkers for CADOSA, and their upregulation was further confirmed by qRT-PCR. Notably, S100A12 expression was correlated with increased monocyte infiltration, highlighting its role in inflammatory pathogenesis of CADOSA.

Conclusions: These findings reveal immune-metabolic dysregulation underlying CADOSA and provide potential diagnostic biomarkers and targeted therapeutic targets (S100A12 and MMP9) for CADOSA patients.

综合转录组学分析揭示了冠状动脉疾病和阻塞性睡眠呼吸暂停共病的诊断生物标志物。
背景:冠状动脉疾病(CAD)和阻塞性睡眠呼吸暂停(OSA)共同发生,被称为CADOSA,其临床结果比单独发生任何一种情况更差,但其分子机制尚不清楚,需要发现生物标志物以改善诊断和个性化管理。方法:本研究招募了96名年龄匹配的参与者(24名健康对照,25名CAD, 23名OSA和24名CADOSA)进行临床评估和PBMC转录组学分析。综合生物信息学分析包括差异基因表达(edgeR/DESeq2)、途径富集、蛋白质相互作用网络和拓扑分析、基于机器学习的生物标志物选择和免疫细胞浸润评估。结果:与CAD或OSA的单一疾病相比,CADOSA患者有更严重的心功能障碍(左心室增大)、呼吸障碍(呼吸暂停低通气指数升高)和代谢紊乱(甘油三酯/肌酐升高)。与健康对照组相比,转录组学鉴定出832个cad特异性基因,166个osa特异性基因和376个cadosa特异性基因。CADOSA表现出共同的(efferocytosis受损,中性粒细胞胞外陷阱和细胞骨架异常)和独特的富集通路(nod样受体/PPAR信号通路),主要与免疫或代谢失调相关。S100A12和MMP9基因的表达增强(AUC分别为0.83和0.78)被确定为CADOSA的潜在生物标志物,并通过qRT-PCR进一步证实其上调。值得注意的是,S100A12表达与单核细胞浸润增加相关,突出了其在CADOSA炎症发病中的作用。结论:这些发现揭示了CADOSA患者的免疫代谢失调,并为CADOSA患者提供了潜在的诊断生物标志物和靶向治疗靶点(S100A12和MMP9)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Cardiovascular Medicine
Frontiers in Cardiovascular Medicine Medicine-Cardiology and Cardiovascular Medicine
CiteScore
3.80
自引率
11.10%
发文量
3529
审稿时长
14 weeks
期刊介绍: Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers? At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信